James Barry - 09 Nov 2026 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 10:56:51 UTC
Prior SEC filing
09 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ James Barry
Filing notes and source

Key filing fact

James Barry filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 12 Nov 2026.

Key facts

  • This page summarizes James Barry's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2026, 10:56.

Change

  • Previous filing in this sequence was filed on 09 Sep 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002022345 Primary reporting owner

BARRY JAMES

Relationship
EVP, President, LSG
Address
C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES
Signature
/s/ James Barry
Signature date
10 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIO transaction

Bio-Rad A Common Stock

Sale

Transaction value
Shares
-1,400
Change %
-69%
Price
$385.63*
Shares after
625
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.588 to $385.645, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .